Amicus Therapeutics

Yahoo Finance • 3 months ago

JPMorgan Chase & Co's Strategic Reduction in Amicus Therapeutics Inc

On September 30, 2024, JPMorgan Chase & Co executed a significant transaction by reducing its holdings in Amicus Therapeutics Inc (NASDAQ:FOLD) by 2,047,098 shares. This move adjusted the firm's total shares in Amicus to 12,823,682, reflec... Full story

Yahoo Finance • 3 months ago

Is Amicus Therapeutics, Inc. (FOLD) the Best Guru Stock To Buy Now?

We recently compiled a list of the 10 Best Guru Stocks To Buy Now. In this article, we will have a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) ranks among the best guru stocks to buy now. Due to the plethora of investment option... Full story

Yahoo Finance • 3 months ago

Wall Street indexes bounce back as investors await inflation data, Fed rate cuts

Wall Street's three major indexes gained more than 1% on Monday as investors looked for bargains after the previous week's sell-off while they also waited for inflation reports in coming days and the Federal Reserve's next policy decision... Full story

Yahoo Finance • 4 months ago

High Growth Tech Stocks To Watch In The United States

Over the last 7 days, the market has remained flat, but it is up 23% over the past year with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks that align with these optimistic projections c... Full story

Yahoo Finance • 10 months ago

20 Fastest Growing Biotech Companies in the US

In this article, we will be taking a look at the 20 fastest growing biotech companies in the US. If you are not interested in learning about the landscape of biotech companies, head straight to the 5 Fastest Growing Biotech Companies In Th... Full story

Yahoo Finance • 11 months ago

Amicus Therapeutics Inc Chief Accounting Officer Sells Company Shares

Chief Accounting Officer Samantha Prout of Amicus Therapeutics Inc (NASDAQ:FOLD) has sold 32,104 shares of the company on January 9, 2024, according to a recent SEC Filing. This transaction has been part of a series of sales by the insider... Full story

Yahoo Finance • 12 months ago

15 Best Growth Stocks to Buy Under $25

In this article, we present 15 best growth stocks under $25. If you want to skip our discussion on the performance of growth stocks, head directly to 5 Best Growth Stocks Under $25. The markets have rallied for the better part of the year... Full story

Yahoo Finance • last year

Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO

Amicus Therapeutics, Inc. Crowley to Step Down from Amicus Board of Directors in March 2024 and Become Amicus Chairman Emeritus Michael Raab, Current Lead Independent Director, to Become Chairman of Amicus Board of Directors PRINCETON,... Full story

Yahoo Finance • last year

Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates

3Q 2023 Total Revenue of $103.5M, a 27% Increase Year-Over-Year and 22% at CER Galafold® Quarterly Revenue Surpasses $100M for the First Time Increasing FY 2023 Galafold® Revenue Growth Guidance to 16%-18% at CER Pombiliti™+ Opfolda™ Ap... Full story

Yahoo Finance • last year

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023

PRINCETON, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November. UBS Biopharma Conference... Full story

Yahoo Finance • last year

Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023

PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023, at 8:30 a.m. ET to discuss financia... Full story

Yahoo Finance • last year

Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023

PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and four posters highlighting its development program for Pompe disease will be included at the 28th Annual... Full story

Yahoo Finance • last year

Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration

Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule Blackstone to also Purchase $30M of Amicus Common Stock PRINCETON, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global,... Full story

Yahoo Finance • last year

Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease

Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease AmicusTherapeuticstoHostConferenceCallTodayat... Full story

Yahoo Finance • last year

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023

PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Morgan Stanley 21st Annua... Full story

Yahoo Finance • last year

Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023

PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at the Society for the Study of Inborn Error... Full story

Yahoo Finance • last year

Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare d... Full story

Yahoo Finance • last year

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom

Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain National Institute for Health and Care Excellence (NICE) Issues Final Positive Recommendation PHILADELPHIA... Full story

Yahoo Finance • last year

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union

PHILADELPHIA, June 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Eu... Full story

Yahoo Finance • 2 years ago

Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates

1Q23 Revenue Growth of 14% at CER to $86.3M On Track to Deliver Full-Year 2023 Galafold Revenue Growth of 12%-17% at CER U.S. FDA Pre-approval Inspection for AT-GAA Complete; Approval Expected 3Q 2023 European Launch of Pombiliti®+Opfol... Full story